Live Breaking News & Updates on Pending Health Canada

Stay updated with breaking news from Pending health canada. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Aptorum Group Announces Submission of Clinical Trial Application for ALS-4, an Orally Administered Small Molecule Drug for the Treatment of Infections caused by Staphylococcus aureus including Methicillin-resistant Staphylococcus aureus (MRSA)

Aptorum Group Limited
Aptorum Group Announces Submission of Clinical Trial Application for ALS-4, an Orally Administered Small Molecule Drug for the Treatment of Infections caused by Staphylococcus aureus including Methicillin-resistant Staphylococcus aureus (MRSA)
Tuesday, December 22, 2020 8:35PM IST (3:05PM GMT)

Regulatory News:

Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a biopharmaceutical company focused on novel technologies for the treatment of a variety of medical conditions including infectious diseases, announced that the company, through its wholly owned subsidiary Aptorum International Limited, has submitted a Clinical Trial Application (CTA) with the Public Health Agency of Canada (Health Canada) to conduct a Phase 1 clinical trial of ALS-4, an orally administered small molecule drug for the treatment of infections caused by ....

New York , United States , France General , Clark Cheng , Ghislaine Gasparetto , Aptorum Group Form , Aptorum Group Or , Investor Relations Department , Public Health Agency Of Canada , Daptorum Group , Financial Communications Europe , Aptorum Group Limited Nasdaq , Aptorum International , Financial Communications United States , Health Canada , Aptorum Group Acticule , United Kingdom , Group Limited , Euronext Paris , Aptorum International Limited , Clinical Trial Application , Public Health Agency , Methicillin Resistant Staphylococcus , Pending Health Canada , Chief Medical Officer , Executive Director ,

Redirecting to Aptorum Group Announces Submission of Clinical Trial Application for ALS-4, an Orally Administered Small Molecule Drug for the Treatment of Infections caused by Staphylococcus aureus including Methicillin-resistant Staphylococcus aureus (MRSA)

December 22, 2020 healthcare
Aptorum Group Announces Submission of Clinical Trial Application for ALS-4, an Orally Administered Small Molecule Drug for the Treatment of Infections caused by Staphylococcus aureus including Methicillin-resistant Staphylococcus aureus (MRSA)
Regulatory News:
Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a biopharmaceutical company focused on novel technologies for the treatment of a variety of medical conditions including infectious diseases, announced that the company, through its wholly owned subsidiary Aptorum International Limited, has submitted a Clinical Trial Application (CTA) with the Public Health Agency of Canada (Health Canada) to conduct a Phase 1 clinical trial of ALS-4, an orally administered small molecule drug for the treatment of infections caused by Staphylococcus aureus including Methicillin-resistant Staphylococcus aureus (MRSA). Pending Heal ....

Clark Cheng , Aptorum Group Form , Aptorum Group Or , Public Health Agency Of Canada , Daptorum Group , Aptorum Group Limited Nasdaq , Aptorum International , Health Canada , Aptorum Group Acticule , Regulatory News , Group Limited , Euronext Paris , Aptorum International Limited , Clinical Trial Application , Public Health Agency , Methicillin Resistant Staphylococcus , Pending Health Canada , Chief Medical Officer , Executive Director , Aptorum Group Limited , Private Securities Litigation Reform Act , French Autorit , Des March , Regulations Delegated , கிளார்க் செங் , ஆரோக்கியம் கனடா ,